Meeting Coverage

“With lung cancer we’re treating more patients effectively today and even curing them because we’re using our most effective therapies earlier.”

Selecting a treatment for operable non-small cell lung cancer from the many options available involves consideration of tumor stage and biomarkers.

Check out the key presentations from AAN Fall Clinical on MS. And follow along for more from AAN.

Educational and research gaps in treating plaque psoriasis in patients with skin of color can lead to delays in diagnosis and treatment.

Take a look at the schedule for AAN Fall Conference. And follow along at PW for conference coverage.

Take a look at some of the fun facts about AAN Fall Conference. And follow PW for conference coverage.

For a retrospective study involving 607 oncology patients treated from 2014-2019, the potential for predicting patient prognosis and guiding immunotherapy treatment through the analysis of total tumor volume (TTV) and artificial intelligence (AI) tumor heterogeneity from CT scans was investigated.

In early-stage non-small cell lung cancer (NSCLC), the recommended treatment options include targeted and immune therapies.

In the management of early-stage non-small cell lung cancer (eNSCLC), the introduction of PD-1/PD-L1 checkpoint inhibitors has marked a significant advancement.